Table 1. Trial treatment.

Drug	Dose/potency	Dose frequency	Route of administration	Regimen/treatment period	Use
Pembrolizumab	200 mg	Q3W	IV infusion	Q3W; day 1 of each 3-week cycle from cycle 2	Experimental
Olaparib	300 mg	BID	Oral	During each treatment cycle	Experimental
Bevacizumab	15 or 7.5 mg/kg	Q3W	IV infusion	Q3W; day 1 of each 3-week cycle	Background therapy

BID, twice daily; IV, intravenous; Q3W, every 3 weeks